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Abstract
Targeting the renin-angiotensin system is proposed to affect mortality due to coronavirus disease 2019 (COVID-19). We 
aimed to compare the mortality rates in COVID-19 patients who received angiotensin-converting enzyme inhibitors or 
angiotensin receptor blockers (ACEIs/ARBs) and those who did not. In this retrospective cohort study, mortality was con-
sidered as the main outcome measure. All underlying diseases were assessed by the chronic use of medications related to 
each condition. We defined two main groups based on the ACEIs/ARBs administration. A logistic regression model was 
designed to define independent predictors of mortality as well as a Cox regression analysis. In total, 2553 patients were 
included in this study. The mortality frequency was higher in patients with a history of underlying diseases (22.4% vs 12.7%, 
P value < 0.001). The mortality rate in patients who received ACEIs/ARBs were higher than non-receivers (29.3% vs. 19.5%, 
P value = 0.013, OR = 1.3, 95% CI 1.1, 1.7) in the univariate analysis. However, the use of ACEIs/ARBs was a protective 
factor against mortality in the model when adjusted for underlying conditions, length of stay, age, gender, and ICU admis-
sion (P value < 0.001, OR = 0.5, 95% CI 0.3, 0.7). The Kaplan–Meier curve showed an overall survival of approximately 
85.7% after a 120-day follow-up. ACEIs/ARBs are protective factors against mortality in COVID-19 patients with HTN, 
and these agents can be considered potential therapeutic options in this disease. The survival probability is higher in ACEIs/
ARBs receivers than non-receivers.
Keywords Angiotensin-converting enzyme inhibitors (ACEIs) · Angiotensin receptor antagonists · COVID-19 · SARS-
CoV-2 · Hypertension · Mortality · Renin-angiotensin system · Survival analysis
Introduction
As of September 21st, more than 30,000,000 cases of coro-
navirus disease 2019 (COVID-19) and more than 900,000 
deaths have been reported [1]. A considerable number of 
victims have pre-existing comorbidities: hypertension 
(HTN) (30%), diabetes mellitus (DM) (20%), coronary 
artery disease (CAD) (6%), and vascular diseases of the 
central nervous system (3%) [2, 3]. Many of the patients suf-
fering from such comorbidities receive the renin-angiotensin 
system (RAS) inhibitors to regulate blood pressure.
Until now, no specific medication is available for the 
treatment of COVID-19, and the current guidelines are 
focused on reducing the probability of transmission by 
enforcing physical distancing, isolation, and supportive 
interventions in positive cases [4]. Several medications have 
been proposed, one of which is based on targeting the angi-
otensin-converting enzyme 2 (ACE2) receptor with special 
recombinant molecules [5].
Studies have revealed that based on the biochemical 
and crystal structure of severe acute respiratory syndrome 
coronavirus (SARS-CoV), this virus’s surface glycoprotein 
exhibits a high affinity for the human ACE2 receptor. Since 
the structural amino acid sequence of SARS-CoV-2 is 76.5% 
similar to its predecessor, SARS-CoV, the mentioned surface 
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proteins are mostly homologous. However, further studies 
revealed that SARS-CoV-2 shows greater efficiency in bind-
ing to the ACE2 receptor than SARS-CoV, hence the for-
mer’s higher virulence. This surface protein is essential for 
detection of and entry to the host cells [6, 7]. Overexpression 
of the ACE2 receptor was associated with aggravated dis-
ease in animal models and, by facilitating the virus’s entry, 
it resulted in increased damage to the lung tissue. On the 
other hand, the inhibition of RAS, which is dependent on 
the ACE expression, results in the improvement of pulmo-
nary symptoms, probably by increasing anti-inflammatory 
mediators [8]. Besides, a study on mice, revealed that the 
administration of RAS inhibitors is associated with reduced 
pulmonary inflammatory response and mortality [9].
Accordingly, it is inferred that the compromised pul-
monary protection caused by the novel virus, is one of the 
reasons for the high mortality rate. The ACE2 receptor is 
expressed on the surface of different tissues, such as the 
intestinal lining, heart, lungs, kidneys, and liver [10, 11]. 
The vast distribution of ACE2 receptors on the surface of 
various types of cells throughout the body also explains the 
possible cause behind multi-organ failure in severe cases 
[12, 13]. Targeting the ACE/angiotensin II/angiotensin I 
receptor (ACE/AngII/ATIR) is proposed as a novel man-
agement strategy in patients suffering from HTN. Angioten-
sin-converting enzyme inhibitors (ACEIs) and angiotensin 
receptor blockers (ARBs) are capable of targeting the ACE/
AngII/ATIR signaling pathway, as well as impacting the 
ACE/Ang receptor expression [14]. But it remains unknown 
if RAS inhibitors have clinical implications in COVID-19 
treatment. Considering that the clinical effects of ACEIs/
ARBs on the outcome of COVID-19 are currently unclear, 
this study’s primary objective is to compare the mortality 
rate in COVID-19 patients who received ACEIs/ARBs and 
those who did not.
Methods
In this retrospective cohort study, patients diagnosed with 
COVID-19 (according to World Health Organization interim 
guidance [15]), admitted to 17 referral hospitals affiliated to 
Iran University of medical sciences (IUMS) between Feb-
ruary 20th and April 4th were enrolled. The main outcome 
measure in this study was considered mortality. The data 
were collected from the SEPAS system, a national integrated 
care electronic health record system [16]. The data gather-
ing process is an automatic procedure. Whenever a patient 
is admitted to a hospital, the data (personal information, 
diagnosis, discharge information, all services, and adminis-
tered medications) are captured in real-time. Since the least 
amount of human involvement is present in the data entry 
process, and a machine captures the data, it is reliable and 
consistent.
Eligibility criteria were: hospitalization due to COVID-19 
and an age above 18 years. Recorded data included demo-
graphic variables, underlying comorbidities including DM, 
HTN, chronic kidney disease (CKD), chronic pulmonary dis-
eases (CPD), malignancies, cardiovascular diseases (CVD), 
chronic use of immunosuppressive medications, intensive 
care unit (ICU) admission, length of hospital stay (LOS) and 
clinical outcomes (death/recovery). Patients were followed 
after discharge for at least 120 days. It should be mentioned 
that HTN was included as a subgroup of CVD. As of immu-
nosuppressant medications, all patients who received any of 
the drugs in the following classes chronically were included: 
calcineurin inhibitors, anti-proliferative agents, mammalian 
target of rapamycin inhibitors, and steroids. Antihyperten-
sive drugs were categorized into five groups: diuretics, cal-
cium channel blockers (CCBs), beta-blockers, ACEIs, and 
ARBs. Based on national guidelines, the protocol for the 
treatment of COVID-19 is hydroxychloroquine plus a com-
bination of lopinavir-ritonavir or ribavirin or oseltamivir 
based on the clinical opinion of admitting physician [17].
All underlying diseases were assessed by the chronic use 
of medications related to each condition. All the patients 
had a history of receiving these medications both before and 
during hospitalization. In this study, we defined two main 
groups based on the administration of ACEIs/ARBs; the 
receivers and non-receivers. All the cases who had a history 
of ICU admission were considered critically ill.
The medical ethics committee of IUMS approved this 
study under the code number of IR.IUMS.REC.1399.200.
Statistical analysis
Categorical variables were described as frequency rates and 
percentages, and continuous variables were described using 
mean and standard deviation (SD) or median and interquar-
tile range (IQR) values with 25th and 75th percentiles in 
the parenthesis. Continuous variables were compared using 
independent samples T-test when the data were normally 
distributed; on the other hand, the Mann–Whitney U test 
was implemented if the data were non-parametric. Regard-
ing categorical variables, proportions were compared using 
the χ2 test. However, if the data were limited, Fisher’s exact 
test was performed. A logistic regression model was used 
to adjust the probable confounding variables. Mortality 
was considered the dependent variable, and each variable 
with a P value less than 0.2 were entered in the model by 
using the “Enter method”. Odds ratios (ORs) and 95% con-
fidence interval (95%CI) were also reported. For survival 
analysis, a Cox regression model was used. Hazard ratios 
(HR) were calculated, and the Kaplan–Meier curve was also 
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implemented to show the survival of ACEIs/ARBs receivers 
versus non-receivers.
All statistical analyses were performed using SPSS ver-
sion 23 (SPSS Inc., Chicago, Illinois). The significance level 
for P-value was considered 0.05.
Results
Baseline characteristics
Among 2553 patients, 1498 (58.7%) were male, and par-
ticipants’ mean age was 58.1 ± 17.9 years. In total, 1569 
(61.5%) patients had a history of an underlying disease 
(still under treatment), and 984 (38.5%) had no history of 
any underlying condition. The rate of underlying diseases 
including CVD, CKD, CPD, DM, malignancy, and chronic 
use of immunosuppressive medications were 36.9%, 9.1%, 
26.9%, 19.5%, 1.7%, and 1.3%, respectively. In cases with 
a history of underlying diseases, frequencies of each condi-
tion for CVD (including HTN) was 942 (60%), CKD 233 
(14.9%), CPD 686 (43.7%), DM 498 (31.7%), malignancy 
43 (2.7%), chronic use of immunosuppressive medications 
34 (2.2%) and HTN 710 (45.3%). Among all patients, 83 
(3.3%) received ACEIs, 444 (17.4%) received ARBs, 189 
(7.4%) received beta-blockers, 265 (10.4%) received CCBs, 
and for 57 (2.2%) of patients, diuretics were prescribed. In 
total, 500 (19.6%) received either ACEIs or ARBs. Twenty-
seven patients had a history of taking both ACEIs and ARBs, 
which was corrected during hospitalization to a prescription 
of one of these classes only. The median of LOS was 5 days, 
with an IQR of 5 (3,8). The number of cases admitted to ICU 
and deceased patients was 1000 (39.2%) and 478 (18.7%), 
respectively. The median follow-up duration was 124 days, 
IQR = 6 (121,127).
Univariate analysis
The frequency of DM, ICU admission, and CPD was higher 
in ACEIs receivers. LOS and mean age were also higher 
in ACEIs receivers when excluding patients who received 
ARBs. The mortality was not significantly different between 
ACEIs receivers and non-receivers (25.0% vs. 17.8%, P 
value = 0.165, OR = 1.5, 95% CI 0.8, 2.8). The frequency of 
chronic use of immunosuppressants, DM, ICU admission, 
CKD, CPD, mortality (22.3% vs. 17.8%, P value = 0.030, 
OR = 1.3, 95% CI 1.0, 1.7) and gender was higher among 
ARBs receivers when excluding patients who received 
ACEIs. LOS and mean age were also higher in ARBs receiv-
ers than non-receivers (Table 1).
The rate of all underlying conditions was higher in ACEIs/
ARBs receivers except for malignancy (P value = 0.348). 
Receivers of ACEIs/ARBs had a higher mean age, and the 
frequency of male patients was higher in non-receivers. 
LOS, ICU admission rate, and concurrent use of other anti-
hypertensive medications are also demonstrated in Table 1.
There was no significant difference between mortality of 
male and female patients (P value = 0.056), but the mean age 
was significantly higher in deceased cases (Table 2). The use 
of all antihypertensive medications was found to be more 
frequent in deceased patients. The frequency of mortality 
was significantly higher in patients with a history of underly-
ing conditions with the chronic use of immunosuppressants 
as the foremost risk factor for mortality (Table 2). Attribut-
able mortality risks of CVD, CKD, CPD, DM, malignancy, 
chronic use of immunosuppressive medications, and HTN 
were calculated as 11.2%, 5.8%, 11.8%, 10.2%, 16.4%, 
46.9%, and 9.9%, respectively.
Multivariable analysis
A logistic regression model was designed with mortality 
as the dependent variable and ACEIs/ARBs administra-
tion, CVD, CKD, CPD, DM, malignancy, and chronic use 
of immunosuppressants, age, gender, ICU admission, LOS, 
CCBs, diuretics, and beta-blockers as independent variables. 
The variables which were entered in the model had a P value 
of less than 0.2 in univariate analysis. All ORs were reduced 
after entering the model except for gender and malignancy. 
CVD and DM were not statistically significant in the model 
(P value > 0.05) although they were significant in univariate 
analysis (CVD: OR = 2.0, 95% CI 1.6, 2.4, P value < 0.001 
and DM: OR = 1.8, 95% CI 1.4, 2.3, P value < 0.001). 
Unlike the results of univariate analysis (29.3% vs. 19.5%, 
P value = 0.013, OR = 1.3, 95% CI 1.1, 1.7), the administra-
tion of ACEIs/ARBs was shown to be a protective factor 
against mortality in the model (P value < 0.001, OR = 0.5, 
95% CI 0.3, 0.7). CKD, CVD, DM, and ICU admission were 
confounding ACEIs/ARBs administration in the model in 
a way that, after adjustment, ACEIs/ARBs administration 
became a protective factor (Table 3).
Cox regression and Kaplan–Meier survival analyses 
were performed. The event was considered as death due to 
COVID-19 and time as the duration of follow-up. All vari-
ables with a P value of less than 0.2 in univariate analysis 
were entered into the model with a “backward conditional 
method”. These variables included ACEIs/ARBs adminis-
tration, CVD, CKD, CPD, DM, malignancy, chronic use of 
immunosuppressants, ICU admission, gender, age, CCBs, 
beta-blockers, and diuretics. CVD, CKD, beta-blockers, 
CCBs, and diuretics were omitted from the model in 5 con-
sequent steps. The chronic use of immunosuppressants had 
the highest HR (HR = 3.1, 95% CI 2.0, 4.8, P value < 0.001). 
Patients with a history of ACEIs/ARBs administration had 
a lower risk of mortality than non-receivers (HR = 0.7, 95% 
CI 0.6, 0.9, P value = 0.008). In addition to the chronic 
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use of immunosuppressants, a history of CPD and malig-
nancy along with age and ICU admission were statisti-
cally significant in the Cox regression model (Table 4). 
The Kaplan–Meier curve showed a survival rate of 98.0%, 
92.7%, 86.4%, and 85.7% in all patients recorded at 3rd, 
7th, 26th days, and at the end of the study, respectively. The 
survival curve of ACEIs/ARBs receivers and non-receivers 
is demonstrated in Fig. 1.
Discussion
Among 2553 cases, 61.4% had a history of at least one 
underlying condition. Mean age, ICU admission rate, LOS, 
and mortality rate were higher in this group than patients 
without underlying disease. The most common underlying 
condition was CVD, followed by HTN, CPD, and DM.
There is still much controversy on whether taking ACEIs 
or ARBs are protective or risk factors of mortality in 
COVID-19. ACEIs and ARBs have been compared to a dou-
ble-edged sword. It is claimed that the SARS CoV-2 virus 
has a high affinity to ACE2 and employs this molecule as 
an entry pathway to its target cells. In one pathophysiologic 
view taking ACEIs and ARBs upregulates ACE2 expression 
and provides more opportunity for the virus to enter host 
cells [18]. On the other hand, several studies suggest that 
ACE2 has an anti-inflammatory and protective effect, espe-
cially on the respiratory system, by changing angiotensin 
II to angiotensin (1–7). In this view, the administration of 
ACEIs/ARBs could help the respiratory system to respond 
more efficiently to the infection with SARS-CoV2 [19].
Several studies on SARS-COV and Middle East res-
piratory syndrome coronavirus showed that ACE2 recep-
tors would downregulate due to interaction with the virus 
[20], the opposite of what would happen after ACEIs/ARBs 
administration. As a result of this virus-induced ACE2 
downregulation, angiotensin (1–7) formation is reduced 
with consequent accumulation of angiotensin II. The exces-
sive angiotensin II levels would favor pulmonary edema and 
inflammation, directly associated with angiotensin II lev-
els. ARBs on the other hand, blocked such effects in some 
experimental models [21].
Table 2  Comparison of 
demographics, length of stay, 
intensive care unit admission 
rate, antihypertensive 
medications, and underlying 
conditions in deceased and 
survived COVID-19 patients
a Length of stay
b Intensive care unit
c Chronic kidney disease
d Chronic pulmonary disease
e Diabetes mellitus
f Calcium channel blockers
g Angiotensin converting enzyme inhibitors
h Angiotensin receptor blockers
i For every 10 years increase





Gender (male) 62.5% 57.7% 1.2 (0.9, 1.5) 0.056
Age 68.9 ± 15.6 55.5 ± 17.5 1.5i (1.4, 1.6)  < 0.001
LOSa Median = 6, 
IQR = 7 (3,10)
Median = 5, 
IQR = 5 (3,8)
1.1 (1.0, 1.2)  < 0.001
ICUb admission 56.4% 35.1% 2.4 (1.9, 2.9)  < 0.001
CVD 50.8% 33.6% 2.0 (1.6, 2.5)  < 0.001
CKDc 11.7% 8.5% 1.4 (1.0, 1.9) 0.029
CPDd 39.3% 24.0% 2.0 (1.6, 2.5)  < 0.001
DMe 28.0% 17.5% 1.8 (1.4, 2.3)  < 0.001
malignancy 3.1% 1.3% 2.4 (1.2, 4.4) 0.006
Chronic use of immuno-
suppressants
4.6% 0.6% 8.3 (4.0, 16.9)  < 0.001
CCBf 17.3% 8.7% 2.2 (1.6, 2.9)  < 0.001
Diuretics 4.6% 3.2% 2.8 (1.6, 4.8)  < 0.001
Beta blockers 12.1% 6.3% 2.0 (1.5, 2.8)  < 0.001
HTN 38.7% 25.5% 1.8 (1.5, 2.3)  < 0.001
ACEIsg/ARBsh 23.6% 18.6% 1.3 (1.0, 1.7) 0.013
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The beneficial effects of angiotensin (1–7) on the oxy-
genation, inflammatory cells infiltration, and fibrosis in an 
ARDS experimental model in the acute and late phases were 
demonstrated [22]. It is shown that angiotensin (1–7) has a 
protective role against inflammation, while angiotensin II is 
increased as a result of ACE2 downregulation and causes 
deleterious inflammatory effects in lung and is not inhibited 
by any of the ACEIs [23].
Furthermore, angiotensin (1–7) is produced by ACE2 
with angiotensin II as a substrate, or due to angiotensin (1–9) 
metabolism by ACE1. Thus, under certain conditions and 
depending on the enzymes and substrates’ local concentra-
tions, the RAS might favor angiotensin (1–7) rather than 
angiotensin II production, and ultimately vasodilator effects 
will be dominant [24].
It was demonstrated that Lisinopril and Losartan caused 
the upregulation of ACE2 in animal models by 5 and 3 
times, respectively. They also increased cardiac ACE2 gene 
expression and angiotensin (1–7)’s plasma levels [25].
A study with a small sample size suggested that ACEIs/
ARBs can improve the clinical outcome of COVID-19 
patients with HTN [26]. The results of our study demonstrate 
Table 3  The logistic regression 
model for prediction of 
mortality
Model is adjusted for angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, cardiovas-
cular disease, chronic kidney disease, chronic pulmonary disease, diabetes mellitus, intensive care unit, 
diuretics, beta-blockers, and calcium channel blockers
a Angiotensin-converting enzyme inhibitors
b Angiotensin receptor blockers
c Cardiovascular disease
d Chronic kidney disease
e Chronic pulmonary disease
f Confidence interval
g Diabetes mellitus
h Intensive care unit
i Odds ratio
j For every 10 years increase
Variable Unadjusted  ORi (95%  CIf) Adjusted OR (95% CI) P-value
ACEIsa/ARBsb 1.3 (1.1,1.7) 0.5 (0.4,0.7)  < 0.001
CVDc 2.0 (1.7,2.5) 1.1 (0.8,1.5) 0.480
CKDd 1.4 (1.0,1.9) 1.1 (0.7,1.5) 0.658
CPDe 2.0 (1.7,2.5) 1.8 (1.4,2.2)  < 0.001
DMg 1.8 (1.5,2.3) 1.3 (1.0,1.6) 0.073
Malignancy 2.4 (1.2,4.5) 2.7 (1.3,5.3) 0.005
Chronic use of immunosuppressants 8.3 (4.1,16.9) 7.5 (3.3,16.7)  < 0.001
Gender 1.2 (1.0,1.5) 1.2 (1.0,1.6) 0.049
Age 1.5j (1.4,1.6) 1.5 j (1.4,1.6)  < 0.001
LOS 1.07 (1.05,1.09) 1.03 (1.01,1.05) 0.002
ICUh admission 2.4 (1.9,2.9) 1.7 (1.3,2.1)  < 0.001
Diuretics 2.8 (1.6, 4.8) 1.3 (0.7, 2.5) 0.392
Beta-blockers 2.0 (1.5, 2.8) 1.2 (0.8, 1.8) 0.302
Calcium channel blockers 2.2 (1.6, 2.9) 1.1 (0.8, 1.6) 0.571
Table 4  The Cox regression model for estimating independent vari-
ables in prediction of time of death due to COVID-19
a Angiotensin-converting enzyme inhibitors
b Angiotensin receptor blockers
c Chronic pulmonary disease
d Confidence interval
e Diabetes mellitus, Intensive care unit
f For every ten years increase
€ Intensive care unit
π Hazard ratio
Variable HRπ 95%  CId P value
ACEIsa/ARBsb usage 0.7 0.6, 0.9 0.002
CPDc 1.6 1.3, 1.9  < 0.001
DMe 1.2 0.9, 1.5 0.077
Malignancy 2.2 1.3, 3.6 0.004
Chronic use of immunosup-
pressants
3.3 2.1, 5.1  < 0.001
Gender 1.2 0.9, 1.4 0.069
Age 1.4f 1.4, 1.5  < 0.001
ICU€ admission 1.6 1.3, 2.0  < 0.001
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that by adjusting for underlying diseases, ICU admission, 
and demographic characteristics, medications that affect the 
RAS system (ACEIs and ARBs) became protective factors 
of mortality. It is claimed that ACE2 expression in patients 
who have not yet encountered the virus can increase the 
chance of developing a high viral load and getting a severe 
form of COVID-19. Once the viral load reaches its maxi-
mum amount, the primary cause leading to the deterioration 
of the clinical condition is the inflammatory response rather 
than the virus’s effect. Here, one can deduce the adminis-
tration of ACEI/ARBs with the mechanisms mentioned 
earlier can attenuate the inflammatory condition, therefore, 
decrease the severity of the disease [27]. This would further 
support our hypothesis that when the disease has progressed 
to the symptomatic stage, the administration of ACEIs/
ARBs will be protective.
We also investigated CCBs, diuretics, and beta-blockers 
in the same logistic regression model. Although the ORs 
decreased, their values remained higher than one and statisti-
cally not significant. Although it has been shown that beta-
blockers can decrease secretion of renin, evidence claims 
that beta-blockers do not change the level of ACE2 expres-
sion [28]. The mechanisms of downregulation of ACE2 
enzyme by SARS-CoV2 and the absence of upregulating 
effects of beta-blockers seem to be the reason behind their 
insignificant role in COVID-19 patients’ survival. Diuretics 
increase the renin secretion through multiple mechanisms, 
but they may not affect the imbalance of ACE2 expression 
induced by SARS-CoV2. Therefore, the protective effects of 
ACEIs/ARBs cannot be observed by diuretics.
ACEIs receivers had higher rates of underlying con-
ditions and higher age, LOS, and ICU admission. 
Although these rates were higher, all except LOS shown 
to be independent risk factors of mortality in COVID-19 
patients, the mortality rate of ACEIs receivers did not 
differ with non-receivers when excluding patients who 
received ARBs. The same could be applied for ARBs 
when ACEIs receivers were excluded except for the unad-
justed mortality rate, which is higher in ARBs receiv-
ers. The differences between only ACEIs and only ARBs 
receivers might be due to the smaller number of patients 
who received ACEIs in total. By increasing the number 
of patients who take ACEIs, one must expect a statisti-
cally significant difference in mortality. Although both of 
these medications increase the expression of ACE2, ACEIs 
only block ACE1 while ARBs block the ultimate receptor 
of angiotensin II. Another reason for the observed differ-
ence could be the different mechanisms of these agents’ 
actions, which require further investigations. Ultimately, 
ACEIs/ARBs receivers were found to have a better sur-
vival probability.
Considering that ACEIs/ARBs are preferred blood pres-
sure regulators in patients with a history of DM, CKD, 
and CVD [29, 30], these variables’ confounding effects 
on ACEIs/ARBs administration can be explained. On the 
other hand, ICU admission as an indicator of the disease’s 
severity is a significant risk factor of mortality, which also 
explains its confounding effects in the model.
Administration of ACEIs/ARBs was shown to be a pro-
tective factor (OR = 0.3) although it was not statistically 
significant, probably due to the sample size being small, in 
a recent study by Yang et al. [31] In another study by Peng 
Zhang et al., in-hospital administration of ACEIs/ARBs in 
patients with concurrent HTN and COVID-19 was found 
to lower mortality risk in these cases (hazard ratio = 0.4) 
[32]. Our findings are also in accordance with the results 
Fig. 1  The survival curve of 
angiotensin-converting enzyme 
inhibitors or angiotensin 
receptor blockers receivers and 
non-receivers. ■ Angiotensin-
converting enzyme inhibitors or 
angiotensin receptor blockers
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of these mentioned studies, which suggest ACEIs/ARBs 
as potential therapeutic options in all COVID-19 patients.
From the beginning of the outbreak, some studies per-
formed survival analyses on COVID-19 patients. A recent 
Brazilian study calculated these patients’ overall survival 
to be approximately 90% [33]. An international study also 
calculated the overall survival of the patients at around 70% 
[34]. Another study reported the overall survival of the His-
panic, African American, and white COVID-19 patients 
to be around 90%, 85%, and 65%, respectively [35]. In all 
these studies, the Kaplan–Meier curves reach a plateau state 
around the 20th to 30th day. The same could be observed in 
our study results in which the plateau is seen on the 25th day. 
It could be claimed that the probability of death becomes 
less likely after 20–30 days from hospitalization by receiving 
standard treatment.
Underlying diseases play an essential role in COVID-19 
deleterious outcomes. Studies in China, Italy, and Singapore 
revealed that the prevalence of HTN, DM, CVD, chronic 
obstructive pulmonary disease (COPD), and CKD among 
COVID-19 patients was approximately 21%, 12%, 10%, 2%, 
and 1%, respectively [26]. The rate of underlying diseases is 
higher in the current study. This difference could be associ-
ated with the case selection method since only hospitalized 
patients were included. Hospitalization policies of included 
healthcare facilities consisted of selecting patients with more 
severe clinical conditions. This can explain relatively higher 
rates of CKD and CPD in this study. Age distribution pat-
tern and overall frequency of underlying diseases in Iran 
compared with the other countries [36] could also account 
for the difference found between this study and the others. 
However, the reported rate of underlying diseases in this 
study is not the highest. For instance, CVD and DM rates in 
an Italian study were 42.5% and 35.5% [37].
In the case of CKD, studies in China showed no signifi-
cant difference in the severity of illness between patients 
with and without a CKD history [38]. A meta-analysis on 
these studies reported that the pooled ORs of CKD are statis-
tically significant and suggests that CKD can be a potential 
risk factor. Although there was no statistically significant 
difference in mortality of patients with and without a CKD 
history, the observation showed that the death rate in patients 
with CKD was higher (11.7% vs 8.5%). It should also be 
noted that the mentioned meta-analysis had its limitations, 
such as small sample size in included studies [39].
AR calculates the number of infected cases among 
the exposed group that can be removed if the exposure is 
removed. It is impossible to calculate AR in most case–con-
trol studies because the incidence cannot be determined 
since participants are selected based on the disease. In this 
instance, the OR approximates the relative risk. Most of the 
recent studies have reported ORs regarding underlying dis-
eases in COVID-19 patients.
In a meta-analysis of Chinese studies, HTN (pooled 
OR = 2.3, 95% CI 1.4, 3.8), CPD (pooled OR = 2.4, 95% 
CI 1.7, 3.4), and CVD (pooled OR = 3.4, 95% CI 1.8, 6.2) 
were observed to be risk factors of mortality in COVID-
19 patients which are relatively close to what the results 
of this study shows [39]. As apparent in our results, one 
could observe dramatic changes in indices, such as OR 
after adjustment. For instance, in a study by Zhou et al., 
HTN, CAD, and DM were identified as significant risk 
factors of mortality in COVID-19 patients with ORs of 
3.0, 21.4, 2.85, respectively. CPD was not a significant 
risk factor of mortality (OR = 5.4, 95% CI 0.9, 30.4), and 
only CAD was adjusted in the regression model. After 
the adjustment, the OR of CAD changed drastically to 2.1 
[40]. We suggest that future studies consider prospective 
designs to report risk and OR, although all indices have 
their advantages.
The chronic use of immunosuppressant medications had 
the highest AR between all underlying conditions. However, 
it had a relatively wide confidence interval, probably due 
to the small sample size. All underlying diseases proved 
to have positive ARs in this study. To the best of authors’ 
knowledge, no study has calculated the ARs of each under-
lying disease in COVID-19 patients. We could not find any 
studies which consider the chronic use of immunosuppres-
sants in COVID-19 patients.
Nevertheless, in a study by the Korean Society of Infec-
tious Diseases and Korea Centers for Disease Control and 
Prevention, 14.8% of deceased patients were immune-com-
promised [41]. The authors considered patients suffering 
from malignancies and transplantation as immune-compro-
mised. With the same definition of immune-compromised 
patients, the mortality rate in our study was 7.5%. The 
advantage of the definition provided in our study is that it 
is considering all possible situations that a patient could be 
considered immunocompromised. The difference in rates 
between our study and the Korean one could be attributed 
to their small sample size. We suggest that future studies be 
designed with proper sample size, control group, and sub-
groups of immune-compromising etiologies.
The database we used consisted of information gathered 
from 17 major hospitals of a highly populated city cover-
ing 5.3 million people. This database updates in real-time, 
and it is accurate and consistent because the least amount 
of human error is involved in the data entry process. As far 
as we investigated the literature, this study has the largest 
sample size regarding this matter up to now. This study also 
included anti-HTN medications other than ACEIs/ARBs to 
compare their effects on mortality. As a secondary goal, we 
also calculated ARs of some frequent underlying diseases. 
Considering that all of our patients were admitted to the 
hospital and had moderate to severe clinical conditions, cal-
culated ARs might be higher than overall ARs in the general 
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population. Therefore, these findings should be generalized 
to the population of the COVID-19 patients with caution.
The obtained results and the previously published evi-
dence [42] suggest that patients who are under treatment 
with ACEIs/ARBs should continue taking their medica-
tions; but deciding whether to initiate administration of these 
agents in COVID-19 patients, needs many further investi-
gations in the form of randomized clinical trials. As for the 
first mechanism of action for ACEIs/ARBs, clinical trials are 
currently investigating the use of human recombinant ACE2 
(hr-ACE2) as a novel therapeutic option for COVID-19 [43].
Limitations
This study’s limitations were that the grade of HTN and the 
duration of ACEIs/ARBs administration were unknown. The 
design was a retrospective cohort and for a definite answer to 
this debate designing randomized clinical trials that consider 
variables mentioned in this article is crucial.
Conclusion
Administration of ACEIs/ARBs in COVID-19 patients with 
concurrent HTN will result in improved clinical outcomes, 
and these medications can be potential therapeutic options 
and increase the survival probability in these cases. Other 
anti-HTN medications did not have a protective effect on 
mortality. Furthermore, COVID-19 patients with a history 
of chronic immunosuppressant administration, malignancy, 
CPD, CVD, DM, HTN, and CKD were found to have an 
increased risk of mortality.
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